TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Physician's Global Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar skin movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall pathological complete response (tpCR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 2 or Higher Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Wall Shear Stress (WSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Renal Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of infections caused by multi-resistant microorganisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: lower extremities joint angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patellar tendon force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Dystrophin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior capsule rupture occurrence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of more than two lines of BSCVA
Endpoint domain: Adverse events/effects
Primary endpoint: Terminal elimination rate constant (Ke) and Half-Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AGE level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in cognitive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: PET-CT Complete Response (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: PET-CT Objective Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful isolation of p16INK4a expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Major cytogenetic or molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of Participants With Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number and percentage of Participants With Adverse Drug Reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinically Significant Vital Sign findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic hypothermia measured by tympanic temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthostatic Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: behavior
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Acceptance of HIV Testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fluid Responsiveness Prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marijuana use
Endpoint domain: Adverse events/effects
Primary endpoint: Time of maximum observed drug concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time-curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell proliferation measured by Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: presence of numbness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of antibiotic-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-Month Change in Language Development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 3-Month Change in Social Development
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: 3-Month Change in Fine Motor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-Month Change in Gross Motor Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduce labor pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum comfort levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With corrected serum calcium (CSC) ≤ 11.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak knee flexion angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak abduction moment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PF-06142562 plasma exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RO in the striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone mineral densitometry measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Survival at 100 Days
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival at 3 Years
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline distance covered in six-minute walk test at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline modified Medical Council Dyspnea score at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Forced Expiratory Volume in 1 second (FEV1) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Propagation of epithelial stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sensation of Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Need for peripheral arterial revascularisation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dosing optimization of E. coli L-asparaginase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects of prednisone versus dexamethasone
Endpoint domain: Adverse events/effects
Primary endpoint: Modified ranking scale (mRS) at 90 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Coronary angiography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FEV1 stabilisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post-operative analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed objective response rate (ORR)
Endpoint domain: Adverse events/effects
Primary endpoint: Pathological complete response (pCR) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Stratum-specific objective response rate sustained for 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective response (complete response + partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease stabilization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety based on adverse event monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Remission/Response (CR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of mortality, necessity for mechanical support due to hemodynamic deterioration, and hospital admission for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline methacholine PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Tracking Error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined unsuccessful PVI or PV reconnection
Endpoint domain: Adverse events/effects
Primary endpoint: Uptake and distribution of the imaging agent 18F-TFB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased total retinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: capillary dropout and/or new abnormal retinal blood vessel growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: measurable macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Pelvic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of FLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Jobs Attained
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Overall Job Attainment Proportion
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Job Participant Composite-hours Worked
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Fugl Meyer Upper Limb Assessment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Adhesions to Uterine Scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fat Volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Safety as Assessed by Blood Lipid Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Joint Count by Physician Exam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Number of participants with active anterior uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of genes that modulate lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With at Least One RBC Transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of patients suffering from treatment related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for methamphetamine (Severity of Dependence Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Craving for methamphetamine (Visual Analog Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Craving for methamphetamine (Stimulant Craving Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrement of pain on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Optimal efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted mean and maximal change from baseline in sGaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Completion of initial FIT screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes at Ferriman-Gallwey score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of escalated starting dose
Endpoint domain: Adverse events/effects
Primary endpoint: Study product-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: CD64 expression on neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contraception counseling and initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoride levels in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of potential clinically significant changes in electrical activity of the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with vital sign abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in nasal congestion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Demoralization of patients and caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants who paid for delivery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Endoscopic Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of ETT positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants remaining at risk of flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Consonants Correct (PCC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P300- Long-latency Auditory Evoked Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of biopsy proven acute rejection
Endpoint domain: Mortality/survival
Primary endpoint: death within six months of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Median Change in Percent Ki-67 From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Toxicity Events by Final Attribution and Treatment Arm
Endpoint domain: Adverse events/effects
Primary endpoint: Family satisfaction with terminal care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfort scale in last two weeks of life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of key descriptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) or Minimum Effective Dose (MED) of N-803
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature changes in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: maximum diameter of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Eye Comfort Index (ECI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: concentrations of plasma homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vascular function, measured as flow mediated vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants Who Progressed or Died
Endpoint domain: Mortality/survival
Primary endpoint: Change in Brain Activation and Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevention of Gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious AEs (SAEs) and Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Physical Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb length discrepancy before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recovery of GI function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and efficacy of NOVA22007
Endpoint domain: Adverse events/effects
Primary endpoint: Opaqueness on X-Ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infusional Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of Graft Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival (PFS-1)
Endpoint domain: Mortality/survival
Primary endpoint: Eating behavior after short sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physical activity after short sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating behavior after long sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical or silent stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in Social anxiety and Avoidance Scale for Adolescents - Anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Social anxiety and Avoidance Scale for Adolescents - Avoidance scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sheehan disability scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Clinical Global Impression Scale for Social Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social Anxiety Session Change Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in diagnostic assignment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Portal blood flow measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of massage intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of massage intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of uncovered scaffold struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit rate (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: somatic changes in tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Long-term control of Graves' disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of desipramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Sleep Apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: WOMAC osteoarthritis index score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Toxicity of MLN9708 when combined with nelfinavir
Endpoint domain: Adverse events/effects
Primary endpoint: Venous thromboembolism (VTE) complications
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of circulating tumor deoxyribonucleic acid (ctDNA) to undetectable levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Ankle dorsiflexion-plantarflexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle inversion-eversion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural sway areas during quiet standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of asymmetric loading in quiet standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Push-off forces during gait initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcaneal lengthening measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Aspiration score at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Restless Legs Syndrome Study Group rating scale for restless legs syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic Lesion detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes